Unknown PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT01924325

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events (ADANCE)

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design

Sponsor: Xijing Hospital

Conditions Ischemic Stroke TIA

Interventions Apixaban Aspirin Clopidogrel placebo

Updated 5 times since 2017 Last updated: Aug 13, 2013 Started: Jan 31, 2014 Primary completion: Dec 31, 2015 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01924325, this PHASE2/PHASE3 trial focuses on Ischemic Stroke and TIA and remains ongoing. Sponsored by Xijing Hospital, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xijing Hospital

Data source: Xijing Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China